Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Stephen L. Dahl"'
Autor:
Kim M. Murray, Stephen L. Dahl
Publikováno v:
Annals of Pharmacotherapy. 31:1335-1338
BACKGROUND: Tumor necrosis factor (TNF) is the dominant mediator of the cytokine cascade that causes inflammation and joint destruction in rheumatoid arthritis. A new class of agents under investigation, the biologic TNF inhibitors, inhibits the acti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3c2df5807be9426735d7a47bafa3721
https://doi.org/10.1177/106002809703101111
https://doi.org/10.1177/106002809703101111
Autor:
Stephen L. Dahl
Publikováno v:
Annals of Pharmacotherapy. 27:456-463
OBJECTIVE: To review the pharmacology, pharmacokinetic disposition, dosage recommendations, adverse effects, drug interactions, and efficacy of nabumetone in patients with selected rheumatic disorders and soft-tissue injuries. DATA SOURCES: Data from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81dcc0df7c18799e6b05abadc07007aa
https://doi.org/10.1177/106002809302700413
https://doi.org/10.1177/106002809302700413
Autor:
Stephen L. Dahl
Publikováno v:
Applied Therapeutics ISBN: 9781349131778
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2ae63f86059194396f291e6b45154cb7
https://doi.org/10.1007/978-1-349-13175-4_75
https://doi.org/10.1007/978-1-349-13175-4_75
Autor:
Stephen L. Dahl
Publikováno v:
Annals of Pharmacotherapy. 28:673-674
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ff9e78e509da9cb09fb9c15098e8448
https://doi.org/10.1177/106002809402800523
https://doi.org/10.1177/106002809402800523
Autor:
Stephen L. Dahl
Publikováno v:
DICP. 24:895-896
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::da77b5ca03ca81d33aaf112858519700
https://doi.org/10.1177/106002809002400937
https://doi.org/10.1177/106002809002400937
Autor:
Stephen L. Dahl, David M. Bamberger
Publikováno v:
Archives of Internal Medicine. 152:554
• Study Objective.— The purpose of this study was to assess and compare the impact of voluntary compliance and enforced compliance with institutional guidelines for initiating third-generation cephalosporin therapy. Design.— An audit of third-g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0f85624a71ad8a9b871a2beaacda91e4
https://doi.org/10.1001/archinte.1992.00400150078014
https://doi.org/10.1001/archinte.1992.00400150078014
Autor:
Stephen L. Dahl, John R. Ward
Publikováno v:
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2:354-365
Benoxaprofen is a nonsteroidal anti-inflammatory agent that belongs to the arylalkanoic acid class of antirheumatic drugs. Animal studies have demonstrated that it has analgesic, antipyretic, and anti-inflammatory properties. Although benoxaprofen is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09a79f93d0ebc94be948c45e7bcc538e
https://doi.org/10.1002/j.1875-9114.1982.tb03212.x
https://doi.org/10.1002/j.1875-9114.1982.tb03212.x
Autor:
Stephen L. Dahl, John R. Ward
Publikováno v:
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2:80-90
Piroxicam, a new non-steroidal anti-inflammatory drug, possesses analgesic, antipyretic, and anti-inflammatory properties and inhibits platelet aggregation in animal models. Its elimination half-life is 38 hours, and hepatic metabolism to inactive me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30097861839b6e0afea80566ec8a5e8e
https://doi.org/10.1002/j.1875-9114.1982.tb03178.x
https://doi.org/10.1002/j.1875-9114.1982.tb03178.x
Publikováno v:
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 6:112-117
To evaluate the effect of cimetidine on serum concentrations of piroxicam, we administered a single 20-mg oral dose of piroxicam to 10 healthy male volunteers on 2 occasions. The first was given on day 1 of the study and the second on day 15, 7 days
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88077d47921cbc125229b1d66232da75
https://doi.org/10.1002/j.1875-9114.1986.tb03464.x
https://doi.org/10.1002/j.1875-9114.1986.tb03464.x
Autor:
Cecil O. Samuelson, Graciela S. Alarcón, Richard P. Polisson, H. James Williams, Stephen L. Dahl, Marlene J. Egger, John R. Ward, Steven R. Weiner, Maria Guttadauria, Robert F. Willkens, Michael E. Luggen, Lynn M. Billingsley, James C. Reading, Cheryl Yarboro
Publikováno v:
Arthritis & Rheumatism. 28:721-730
One hundred eighty-nine patients with rheumatoid arthritis were entered into a prospective, controlled, double-blind multicenter trial comparing placebo and methotrexate (MTX). One hundred ten patients completed 18 weeks of therapy. No remissions wer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b4b66ae0756d69000ce3350ff57d1a5
https://doi.org/10.1002/art.1780280702
https://doi.org/10.1002/art.1780280702